Edition:
India

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

5.15USD
8:10pm IST
Change (% chg)

$0.05 (+0.98%)
Prev Close
$5.10
Open
$5.15
Day's High
$5.15
Day's Low
$5.10
Volume
1,703
Avg. Vol
5,238
52-wk High
$7.55
52-wk Low
$3.75

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  KMDA.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -- -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Kamada Ltd Says Kedrab Has Been Launched In U.S.

* KAMADA LTD - KEDRAB HAS BEEN LAUNCHED IN U.S. Source text for Eikon: Further company coverage:

08 May 2018

BRIEF-Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet For Its Product PPP001 In Israel

* TETRA BIO-PHARMA SIGNS LANDMARK COMMERCIALIZATION TERM SHEET FOR ITS LEAD PHARMACEUTICAL PRODUCT, PPP001, IN ISRAEL

24 Apr 2018

BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin

* KAMADA RECEIVED FEEDBACK FROM FDA ON PROPOSED PHASE 3 PROTOCOL FOR INHALED ALPHA-1-ANTITRYPSIN FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE

23 Apr 2018

BRIEF-Kamada Ltd Q4 Earnings Per Share $0.16

* KAMADA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL-YEAR 2017

07 Feb 2018

BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection

* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION

08 Jan 2018

BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease

* KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE

04 Jan 2018

Earnings vs. Estimates

No consensus analysis data available.